Short Term Trading Week Starting: 13 May, page-170

STTCOMP PTX, FA LONG

Market Cap $17M

Shares on Issue 394.3M

SP $0.044

Overview

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company’s lead drug candidate is PTX-200, which is in Phase II clinical trial for negative breast cancer, as well as Phase IB clinical trial in relapsed and refractory ovarian cancer and acute leukemia; and PTX-100, a treatment that has completed Phase I clinical trial for solid tumors. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited is based in South Melbourne, Australia.

Credit Suisse took position at a buy price of 0.05 cents on 1-9 April 2019.


US based H.C. WAINWRIGHT & CO. EQUITY RESEARCH initiated a coverage recently with a Buy rating and $A0.20 price target.
Regal Funds & Australian Ethical Investments are major shareholders too.

Volume is increasing in the last few days. Plenty of news flow and catalyst in the near term.

Top Holders